このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Asenapine in the Treatment of Older Adults With Bipolar Disorder

2014年12月8日 更新者:Martha Sajatovic、University Hospitals Cleveland Medical Center

Objectives: The investigators propose a first-ever, prospective trial of asenapine in older adults with bipolar disorder (BD) to evaluate effects on mood symptoms, tolerability and functional/general health status. Given the dearth of treatment data on older adults with BD, findings are likely to be of substantial clinical interest, may inform larger future studies and will assist in refining bipolar treatment recommendations.

Hypotheses:

Primary: Asenapine therapy will be associated with reduced bipolar manic and depressive symptoms in older adults with BD.

Secondary: Asenapine therapy will be associated with improved functional and general health status, improved global psychopathology, and good tolerability in older adults with BD.

調査の概要

状態

完了

介入・治療

研究の種類

介入

入学 (実際)

15

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Ohio
      • Cleveland、Ohio、アメリカ、44106
        • University Hospitals Case Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

60年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Subjects must have type I Bipolar disorder by DSM-IV criteria confirmed on the Mini Neuropsychiatric Interview (MINI)
  • Subjects must be age 60 or older
  • Subjects must have sub-optimal response to current psychotropic management including at least one of the following:

    1. Behaviors and symptoms of irritability, agitation, mood lability or diminished ability to interact with others in their place of residence
    2. Diminished ability to take care of basic personal needs in their place of residence due to symptoms of BD

Exclusion Criteria:

  • History of intolerance or resistance to asenapine
  • Clinical diagnosis of dementia or Mini-mental state (MMSE) < 24
  • History of TIA, stroke or MI within the past 12 months
  • Medical illness that is the clear, underlying etiology of BD
  • Unstable medical illness or condition including prolonged QT interval, which in the opinion of the study investigators, is likely to affect the outcome of the study or the subject's safety
  • DSM-IV substance dependence (except nicotine or caffeine) within the past 3 months.
  • Rapid cycling BD defined as 4 or more discrete mood episodes within the previous 12 months.
  • At high risk for self-harm or suicide

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Asenapine
12-weeks of open-label asenapine treatment
Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
他の名前:
  • サフリス

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Depressive Symptoms as Measured by the Hamilton Depression Rating Scale (HAM-D)
時間枠:Baseline and 12 weeks
The minimum possible score is 0 and the maximum score is 52. A higher score implies a worse condition.
Baseline and 12 weeks
Change in Manic Symptoms as Measured by the Young Mania Rating Scale (YMRS)
時間枠:Baseline and 12 weeks
The minimum possible score is 0 and the maximum score is 60. A higher score implies a worse condition.
Baseline and 12 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in Global Psychopathology as Measured by the Clinical Global Impression Scale for Use in Bipolar Illness (CGI-BP)
時間枠:Baseline and 12 weeks

The minimum possible score is 1 and the maximum score is 7. A higher score implies a worse condition.

The CGI-BP has three scores - Mania Severity, Depression Severity, and Overall Bipolar Illness Severity.

Baseline and 12 weeks
Change in Perception of Physical Health as Measured by the Short Form General Health Survey (SF-12)
時間枠:Baseline and 12 weeks
The minimum possible score is 1 and the maximum score is 99. A higher score implies a better perceived condition.
Baseline and 12 weeks
Change in Perception of Mental Health as Measured by the Short Form General Health Survey (SF-12)
時間枠:Baseline and 12 weeks
The minimum possible score is 1 and the maximum score is 99. A higher score implies a better perceived condition.
Baseline and 12 weeks
Change in Depressive Symptoms as Measured by the Montgomery Asberg Depression Rating Scale (MADRS)
時間枠:Baseline and 12 weeks
The minimum possible score is 0 and the maximum score is 60. A higher score implies a worse condition.
Baseline and 12 weeks
Change in Bipolar Disorder Symptoms as Measured by the Brief Psychiatric Rating Scale (BPRS)
時間枠:Baseline and 12 weeks
The minimum possible score is 18 and the maximum score is 126. A higher score implies a worse condition.
Baseline and 12 weeks
Change in Cognitive Status as Measured by the Stroop Task
時間枠:Baseline and 12 weeks
The Stroop evaluates patients for cognitive functioning. Patients are to read words aloud or name colors as quickly as possible in a 45-second period. The measure contains three tasks, each associated with a subscale as follows: Word, Color, and Color-Word. Each subscale contains 100 items. The raw score range for each of the subscales is 0-100. Each raw subscale score is converted to a T-Score. The possible T-Score range for the Word subscale is 15 to 85. The possible T-Score range for the Color subscale is 8 to 92. The possible T-Score range for the Color-Word subscale is 3 to 98. Higher scores on the subscales indicate better cognitive functioning. Subscales are scored independently and are not added to produce a total score.
Baseline and 12 weeks
Change in Cognitive Status as Measured by the Trail Making Test
時間枠:Baseline and 12 weeks
The Trails test is a measure of cognitive functioning. The measure consists of two parts: A and B. In part A, participants are asked to draw a trail connecting a series of numbers in sequential order. In Part B, participants are asked to draw a trail connecting a combination of letters and numbers. The time taken to complete each task is noted as the score (e.g., 78 seconds). For Trails A, there is no upper limit on the score, as subjects are given as much time as is needed for them to complete the task. Higher scores indicate poorer cognitive functioning. In Trails B, the task is timed with an upper limit of five minutes. If, at four minutes, it is determined that the subject will not likely complete the task in the time allotted, then the task can be called off. Higher scores indicate poorer cognitive functioning.
Baseline and 12 weeks
Change in Cognitive Status as Measured by the Hopkins Verbal Learning Test (HVLT)
時間枠:Baseline and 12 weeks

Evaluates cognitive functioning across domains: recall, delayed recall, retention, recognition (each scored separately). The scores given are titled: recall score, delayed recall score, retention score, recognition discrimination index. Total Recall score = items correctly recalled (0-36). Delayed Recall score = items correctly recalled following delay (0-12). Retention score = percent items recalled that were also recalled after delay (0-100). The Recognition Discrimination score = true positives minus false positives (0-12). Recall task has 12 words and involves to recall of words after all of them are read aloud to the patient. Delayed recall tasks involves the same twelve words, except recall is tasked after a 20-25 minute delay. Recognition task has 24 words. Patient evaluated on how many from original list he or she is able to recognize. Higher scores = better outcomes.

Total recall scores appear in this entry below.

Baseline and 12 weeks
Change in Cognitive Status as Measured by the Dementia Rating Scale (DRS)
時間枠:Baseline and 12 weeks
The DRS contains items that evaluate cognitive function across 5 subscales: attention, initiation/perseveration, construction, conceptualization, and memory. Subscale raw score ranges are: attention (0-37), initiation/perseveration (0-37), construction (0-6), conceptualization (0-39), and memory (0-25). Raw subscale scores are added for a total raw score with range 0-144. For each raw subscale score, scaled scores are looked up from a battery of 13 tables. Age of the participant determines which table is to be used. Total raw subscale score also has its own scaled score in the tables. In addition to use in determining scaled scores for each of the subscales, these tables are used to look up the scaled score for the total raw score. The tables are contained in the article Robust and Expanded Norms for the Dementia Rating Scale (Pedraza, Lucas, et al. 2010); Archives of Clinical Neuropsychology 25; 347-358. Higher scores, raw and scaled, indicate better cognitive functioning.
Baseline and 12 weeks
World Health Organization Disability Assessment Scale (WHO-DAS)
時間枠:12 weeks
The WHO-DAS II is used to assess patients for difficulties that they experience due to health conditions. Six subscales are represented which cover the following domains: Getting Around (range 1-10), Self Care (range 1-10), Life Activities (range 1-20), Understand/Communicate (range 1-10), Participation in Society (range 1-10), and Getting Along with People (range 1-10). Lower scores represent more positive outcomes, while higher scores represent worse outcomes. Total summary scores were not computed for our analyses and is optional for the measure.
12 weeks
Barnes Drug-induced Akathisia Rating Scale (BARS)
時間枠:Baseline and 12 weeks
This scale is used to measure the presence of akathisia, as may result from use of certain psychotropic medications. The scale contains four items and the score for each item is added to produce the total score. Total scores range from 0 to 14. Higher scores indicate more adverse outcomes.
Baseline and 12 weeks
Assessment of Motor Control Abnormality as Measured by the Simpson Angus Scale (SAS)
時間枠:Baseline and 12 weeks
The Simpson-Angus Scale is used to monitor for neurological and musculoskeletal side effects that may be a result of certain psychotropic medications. The scale consists of 10 questions which each can be rated on a scale of 0 to 4. Scores for each item are added to produce a total score. The highest possible total score is 40. Higher scores indicate more adverse outcomes.
Baseline and 12 weeks
Change in Cognitive Status as Measured by the Hopkins Verbal Learning Test (HVLT)
時間枠:Baseline and 12 weeks

Evaluates cognitive functioning across domains: recall, delayed recall, retention, recognition (each scored separately). The scores given are titled: recall score, delayed recall score, retention score, recognition discrimination index. Total Recall score = items correctly recalled (0-12). Delayed Recall score = items correctly recalled following delay (0-12). Retention score = percent items recalled that were also recalled after delay (0-100). The Recognition Discrimination score = true positives minus false positives (0-12). Recall task has 12 words and involves to recall of words after all of them are read aloud to the patient. Delayed recall tasks involves the same twelve words, except recall is tasked after a 20-25 minute delay. Recognition task has 24 words. Patient evaluated on how many from original list he or she is able to recognize. Higher scores = better outcomes.

Delayed recall scores appear in this entry below.

Baseline and 12 weeks
Change in Cognitive Status as Measured by the Hopkins Verbal Learning Test (HVLT)
時間枠:Baseline and 12 weeks

Evaluates cognitive functioning across domains: recall, delayed recall, retention, recognition (each scored separately). The scores given are titled: recall score, delayed recall score, retention score, recognition discrimination index. Total Recall score = items correctly recalled (0-12). Delayed Recall score = items correctly recalled following delay (0-12). Retention score = percent items recalled that were also recalled after delay (0-100). The Recognition Discrimination score = true positives minus false positives (0-12). Recall task has 12 words and involves to recall of words after all of them are read aloud to the patient. Delayed recall tasks involves the same twelve words, except recall is tasked after a 20-25 minute delay. Recognition task has 24 words. Patient evaluated on how many from original list he or she is able to recognize. Higher scores = better outcomes.

Retention scores appear in this entry below.

Baseline and 12 weeks
Change in Cognitive Status as Measured by the Hopkins Verbal Learning Test (HVLT)
時間枠:Baseline and 12 weeks

Evaluates cognitive functioning across domains: recall, delayed recall, retention, recognition (each scored separately). The scores given are titled: recall score, delayed recall score, retention score, recognition discrimination index. Total Recall score = items correctly recalled (0-12). Delayed Recall score = items correctly recalled following delay (0-12). Retention score = percent items recalled that were also recalled after delay (0-100). The Recognition Discrimination score = true positives minus false positives (0-12). Recall task has 12 words and involves to recall of words after all of them are read aloud to the patient. Delayed recall tasks involves the same twelve words, except recall is tasked after a 20-25 minute delay. Recognition task has 24 words. Patient evaluated on how many from original list he or she is able to recognize. Higher scores = better outcomes.

Recognition Discrimination Index appears in this entry below

Baseline and 12 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Martha Sajatovic, M.D.、University Hospitals Cleveland Medical Center

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2011年10月1日

一次修了 (実際)

2014年3月1日

研究の完了 (実際)

2014年3月1日

試験登録日

最初に提出

2011年10月24日

QC基準を満たした最初の提出物

2011年10月24日

最初の投稿 (見積もり)

2011年10月26日

学習記録の更新

投稿された最後の更新 (見積もり)

2014年12月30日

QC基準を満たした最後の更新が送信されました

2014年12月8日

最終確認日

2014年12月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

双極性障害の臨床試験

購読する